JAZZ - Jazz Pharmaceuticals, Inc.

I wanted to bring this to your attention, possibly a good short term play. Pharmaceuticals has been having alot of good plays and this one, with its low volume could be one of them.



Jazz Pharmaceuticals, Inc. focuses on identifying, developing, and commercializing products for neurology and psychiatry primarily in the United States. Its marketed and approved products include Xyrem for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR, an extended release formulation of fluvoxaminefor, which is a selective serotonin reuptake inhibitor for the treatment of obsessive compulsive disorder and social anxiety disorder. The company?s clinical development pipeline comprises JZP-6, a phase III clinical trial product for the treatment of fibromyalgia; JZP-4, a controlled release formulation of an anticonvulsant for the treatment of epilepsy and bipolar disorder that is in phase II clinical trial; JZP-8, an intranasal formulation of clonazepam for the treatment of recurrent acute repetitive seizures in epilepsy patients, which is in phase II clinical trial; and JZP-7, a transdermal gel formulation of ropinirole for the treatment of restless legs syndrome that is in phase I/II clinical trial. Jazz Pharmaceuticals has a product license agreement with Solvay Pharmaceuticals, Inc. to market Luvox CR and Luvox in the United States; and with GlaxoSmithKline to purchase worldwide rights to the active pharmaceutical ingredient in JZP-4. The company was founded in 2003 and is headquartered in Palo Alto, California.

Jazz Pharmaceuticals Announces Issuance of Key Patent for Once-A-Day LUVOX CR(R)
Thursday December 18, 8:00 am ET


PALO ALTO, Calif., Dec. 18 /PRNewswire-FirstCall/ -- Jazz Pharmaceuticals, Inc. (Nasdaq: JAZZ - News) announced today that the U.S. Patent and Trademark Office has issued U.S. Patent No. 7,465,462 covering its Once-A-Day LUVOX CR® (fluvoxamine maleate) Extended-Release Capsule product. The patent was assigned to Elan Pharma International Limited and is exclusively licensed to Jazz Pharmaceuticals in the United States through a product license agreement with Solvay Pharmaceuticals, Inc. The patent claims the formulation incorporating Elan's SODAS® (Spheroidal Oral Drug Absorption System) technology, as well as a method of using the formulation for the treatment of obsessive compulsive disorder (OCD).
LUVOX CR® was approved on February 28, 2008 by the U.S. Food and Drug Administration (FDA) for the treatment of social anxiety disorder (SAD) and obsessive compulsive disorder (OCD) in adults. The patent has been listed for LUVOX CR® in the FDA Orange Book.

I'm bringing it up as a short play as of tomorrow.

Edit: You know, shorting this wasn't such a bad idea afterall, LOL.